WASHINGTON — In a blow for anti-abortion advocates, the Supreme Court on Thursday rejected a challenge to the abortion pill mifepristone, meaning the commonly used drug can remain widely available.
The court found unanimously that the group of anti-abortion doctors who questioned the Food and Drug Administration’s decisions making it easier to access the pill did not have legal standing to sue.
President Joe Biden said in a statement that while the ruling means the pill can remain easily accessible, "the fight for reproductive freedom continues" in the aftermath of the Supreme Court's ruling two years ago that overturned the abortion-rights landmark Roe v. Wade.
"It does not change the fact that the right for a woman to get the treatment she needs is imperiled if not impossible in many states," he added.
Justice Brett Kavanaugh wrote for the court that while plaintiffs have "sincere legal, moral, ideological, and policy objections to elective abortion and to FDA's relaxed regulation of mifepristone," that does not mean they have a federal case.
The plaintiffs failed to show they had suffered any injury, meaning "the federal courts are the wrong forum for addressing the plaintiffs' concerns about FDA's actions," he added.
"The plaintiffs may present their concerns and objections to the president and FDA in the regulatory process or to Congress and the president in the legislative process," Kavanaugh wrote. "And they may also express their views about abortion and mifepristone to fellow citizens, including in the political and electoral processes."
The legal challenge was brought by doctors and other medical professionals represented by the conservative Christian legal group Alliance Defending Freedom.
"We are disappointed that the Supreme Court did not reach the merits of the FDA’s lawless removal of commonsense safety standards for abortion drugs," said Erin Hawley, one of the group's lawyers. She told reporters she is hopeful the underlying lawsuit can continue because three states — Idaho, Missouri and Kansas — have brought their own claims and have different arguments for standing.
By throwing out the case on such grounds, the court avoided reaching a decision on the legal merits of whether the FDA acted lawfully in lifting various restrictions, including one making the drug obtainable via mail, meaning the same issues could yet return to the court in another case.
Another regulatory decision left in place means women can still obtain the pill within 10 weeks of gestation instead of seven.
Likewise a decision to allow health care providers other than physicians to dispense the pill will remain in effect.
The court's decision to roll back abortion rights two years ago led to a wave of new abortion restrictions in conservative states.
Then, the court suggested it was removing itself from the political debate over abortion, but with litigation continuing to rage over abortion access, the justices continue to play a pivotal role.
Abortion-rights supporters welcomed the ruling, with Nancy Northup, president of the Center for Reproductive Rights, saying she was relieved at the outcome but angered that the case lingered in the court system so long.
"Thank goodness the Supreme Court rejected this unwarranted attempt to curtail access to medication abortion, but the fact remains that this meritless case should never have gotten this far," she said in a statement.
Danco Laboratories, manufacturer of Mifeprex, the brand version of mifepristone, praised the ruling, too, saying it was good for the drug approval process writ large.
In rejecting the challenge, the court "maintained the stability of the FDA drug approval process, which is based on the agency’s expertise and on which patients, health care providers and the U.S. pharmaceutical industry rely," company spokeswoman Abigail Long said.
Anti-abortion groups expressed disappointment, saying the ruling highlighted the importance of this year's election, in which Democrat Biden, who has pledged to defend abortion rights, faces off against Republican Donald Trump, who has the strong backing of conservatives who oppose abortion.
"Joe Biden and the Democrats are hell-bent on forcing abortion on demand any time for any reason, including DIY mail-order abortions, on every state in the country," said Marjorie Dannenfelser, president of SBA Pro-Life America.
If Trump were to win the election, his appointees to the FDA would be in a position to impose new restrictions on mifepristone. Biden’s campaign manager, Julie Chavez Rodriguez, alluded to the possibility in a call with reporters after the ruling. Calling the case “one tactic in a broader, relentless strategy” by anti-abortion activists, Chavez Rodriguez said that if Trump is elected, his advisers and allies would try toban abortion nationwide “without the help of Congress or the court”and also restrict access to contraception — a threat, she said, to blue as well as red states.
The mifepristone dispute is not the only abortion case before the court. It is also due to decide whether Idaho’s strict abortion ban prevents doctors in emergency rooms from performing abortions when a pregnant woman faces dangerous complications.
Mifepristone is used as part of a two-drug FDA-approved regimen that is now the most common form of abortion in the U.S.
Abortion is effectively banned altogether in 14 states, according to the Guttmacher Institute, a research group that backs abortion rights.
The FDA had the backing of the pharmaceutical industry, which has warned that any second-guessing of the approval process by untrained federal judges could cause chaos and deter innovation.
Last year, Texas-based U.S. District Judge Matthew Kacsmaryk issued a sweeping ruling that completely invalidated the FDA’s approval of the pill, leading to panic among abortion-rights activists that it would be banned nationwide.
The Supreme Court put that ruling on hold, meaning the pill remained widely available while litigation continued.
The New Orleans-based 5th U.S. Circuit Court of Appeals in August then narrowed Kacsmaryk’s decision but left in place his conclusion that the FDA’s move to lift restrictions starting in 2016 was unlawful.
Both sides appealed to the Supreme Court. The court in December took up the Biden administration’s appeal in defense of the later FDA decisions, but it opted against hearing the challenge to the original approval of mifepristone in 2000.
The Supreme Court focused solely on the later FDA action, including the initial 2021 decision that made the drug available by mail, which was finalized last year.
